New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 31, 2014
13:47 EDTSNY, REGNRegeneron price target raised to $382 from $362 at Roth Capital
Roth Capital raised its price target on Regeneron (REGN) after the company and partner Sanofi (SNY) presented the full data set from the ODYSSEY MONO study, along with data supporting the potential for once per month dosing with alirocumab. Roth noted that Sanofi is guiding to filing for approval for the drug in 2016.
News For REGN;SNY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 22, 2014
06:34 EDTSNYImmunoGen appoints Richard Gregory as Chief Scientific Officer
ImmunoGen (IMGN) announced the appointment of Richard Gregory as Executive Vice President, Research and Chief Scientific Officer. Gregory will join the company on January 5, 2015, at which time current CSO, John Lambert, will assume the position of Executive Vice President, Distinguished Research Fellow. Gregory most recently served as senior vice president and head of research for the Sanofi (SNY) Genzyme Research & Development Center.
December 12, 2014
08:01 EDTREGNPiper predicts two large-cap biotechs could be acquired in 2015
Subscribe for More Information
December 9, 2014
11:19 EDTSNYSanofi reportedly ready to make acquisitions in animal medicine, Bloomberg says
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use